NasdaqGS:PTCTBiotechs
PTC Therapeutics (PTCT) Launches Sephience After Strong Early Sales And $500 Million Raise
PTC Therapeutics (NasdaqGS:PTCT) has launched Sephience, its newly approved treatment for phenylketonuria, with early sales described as strong.
The company has completed a US$500 million convertible note offering to support future business development activity.
PTC Therapeutics is also working within an ongoing collaboration with Novartis that frames a broader period of change for the business.
For investors following rare disease drug developers, PTC Therapeutics sits at an interesting...